Novartis and Oxford partner on AI in drug development

Swiss pharma giant Novartis (NOVN: VX) is to work with the University of Oxford’s Big Data Institute (BDI) to improve drug research and development using artificial intelligence (AI).

The anonymized data of around five million patients from the UK and international partner organizations, together with findings from relevant Novartis trials will be analyzed over the course of the five-year collaboration.

"This has the potential to transform how we design and conduct our clinical development programs of the future"